Authors
Professor of medicine at Robert Wood Johnson Medical School & medical oncologist at Rutgers Cancer Institute.
Direct of the Center for Healthcare Delivery Science, Beth Israel Deaconess Medical Center
Avi Mamidi, PharmD, RPh, is the director of North America Market Access at ResMed.
Advertisement
Advertisement
Trending on AJMC
1
EHA 2026 Late Breakers Deliver Practice-Shifting Phase 3 Data and Novel CAR T Approaches Across Hematology
2
MRD-Guided CLL Treatment Duration: Personalization or Malpractice?
3
Teclistamab Outperforms Len/Dex in High-Risk Smoldering Myeloma With Higher CR Rate, PFS: Omar Nadeem, MD
4
Tec-Dara Demonstrates Superior 3-Year PFS vs Standard Therapy in Functional High-Risk Myeloma: Rahul Banerjee, MD
5
